US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

HRMY Harmony Biosciences Holdings Inc

29.525

0.655 (2.27%)

31 May 2024 - Cerrado

Retrasado por 15 minutos

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Harmony Biosciences (NASDAQ:HRMY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas Harmony Biosciences.

Harmony Biosciences (NASDAQ:HRMY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas Harmony Biosciences.

Noticias sobre Harmony Biosciences Holdings Inc HRMY

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 31 de Mayo 2024 (1 día hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Viernes 31 de Mayo 2024 (1 día hace) • Edgar (US Regulatory)

Form 8-K - Current report
Miércoles 29 de Mayo 2024 (3 días hace) • Edgar (US Regulatory)

HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
Martes 28 de Mayo 2024 (4 días hace) • PR Newswire (US)

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
Martes 30 de Abril 2024 (1 mes hace) • GlobeNewswire Inc.

Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Martes 30 de Abril 2024 (1 mes hace) • PR Newswire (US)

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
Martes 16 de Abril 2024 (2 meses hace) • PR Newswire (US)

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
Jueves 11 de Abril 2024 (2 meses hace) • PR Newswire (US)

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
Miércoles 3 de Abril 2024 (2 meses hace) • PR Newswire (US)

HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
Martes 26 de Marzo 2024 (2 meses hace) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Lunes 11 de Marzo 2024 (3 meses hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 8 de Marzo 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Harmony Biosciences Holdings Inc Artículos de Noticias

Volvo Car AB (PK)

Vontobel Financial Produ...

BNP Paribas Issuance

Leviathan Lobster Token

France Emprunt D Etat Go...

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones